medigraphic.com
ISSN 2448-5640 (Impreso)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.

2018, Número 1

<< Anterior Siguiente >>

Cir Card Mex 2018; 3 (1)


Trasplante Cardiaco : Ars longa vita brevis

Orozco-Hernández EJ

Idioma: Español
Referencias bibliográficas: 66
Paginas: 7-13
Archivo PDF: 186.86 Kb.


RESUMEN

El trasplante cardiaco esta en su cuarta década como tratamiento para la cardiomiopatía y falla cardiaca avanzada, ha alcanzado un estado de madurez como un tratamiento efectivo, y muchos factores han sido definidos con estandares de excelencia. Aun así, muchas áreas permanecen en constante desarrollo, y avances significativos son reconocidos continuamente. Trasplante cardiaco es el tratamiento de elección para muchos pacientes con falla cardiaca terminal, que permanecen sintomáticos a pesar de máxima terapia médica. Para pacientes cuidadosamente seleccionados, el trasplante impacta importantemente en la sobrevida y calidad de vida. Por otro lado, los dispositivos de asistencia ventricular izquierda (LVAD) han probado ser efectivos, tanto en mejorar sobrevida y calidad de vida en esta clase de pacientes. El equipo multidisciplinario de falla cardiaca, tiene que lidiar con el reto de identificar, que pacientes se benefician mas con trasplante, comparados con la implantación de un LVAD, en el momento apropiado. La estratificacion de riesgos, en estos pacientes con falla cardiaca terminal, es esencial para definir y priorizar los beneficios a obtener, particularmente porque el número de donadores es insuficiente para satisfacer la demanda de receptores . Las indicaciones para trasplante y LVAD, revisión de los componentes de su evaluación preoperatoria, contraindicaciones, resultados, incluyendo sobrevida y complicaciones son revisados.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Alraies MC, Eckman P. Adult heart transplant: indications and outcomes. J ThoracDis 2014;6(8):1120-1128. doi: 10.3978/j.issn.2072-1439.2014.06.44.

  2. 2009 annual report of the U.S. organ procurement and transplantation networkand the scientific registry of transplant recipients: Transplant data 1999-2008. U.S.department of health and human services, health resources and services administration,healthcare systems bureau, division of transplantation, rockville, MD.Available online: http://www.ustransplant.org/annual_reports/current/. AccessedFebruary 1, 2014.

  3. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated intothe ACC/AHA 2005 guidelines for the diagnosis and management of heart failurein adults: A report of the american college of cardiology foundation/americanheart association task force on practice guidelines: Developed in collaborationwith the international society for heart and lung transplantation. Circulation2009;119:e391-479.

  4. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The registry of the internationalsociety for heart and lung transplantation . Twenty-eighth adult heart transplantreport--2011. J Heart Lung Transplant 2011;30:1078-94.

  5. Lietz K, Miller LW. Improved survival of patients with end-stage heart failurelisted for heart transplantation: Analysis of organ procurement and transplantationnetwork/U.S. united network of organ sharing data, 1990 to 2005. J Am Coll Cardiol2007;50:1282-90.

  6. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the managementof heart failure: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol2013;62:e147-239.

  7. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation:International society for heart and lung transplantation guidelines for the careof cardiac transplant candidates--2006. J Heart Lung Transplant 2006;25:1024-42.

  8. Starling RC. Advanced heart failure: Transplantation, LVADs, and beyond. CleveClin J Med 2013;80:33-40.

  9. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHAguidelines for the diagnosis and management of heart failure in adults: A reportof the american college of cardiology foundation/american heart association taskforce on practice guidelines: Developed in collaboration with the internationalsociety for heart and lung transplantation. Circulation 2009;119:1977-2016. 12.

  10. Ammirati E, Oliva F, Cannata A, et al. Current Indications for Heart Transplantationand Left Ventricular Assitance Device: A practical point of view. Eur J ofInternal Medicine 2014;25: 422-429.

  11. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al.The SeattleHeart Failure Model: prediction of survival in heart failure. Circulation2006;113:1424–33.

  12. Smits JM, de Vries E, De Pauw M, Zuckermann A, Rahmel A,Meiser B, et al. Is ittimefor a cardiac allocation score? First results from the Eurotransplant pilot studyon asurvival benefit-based heart allocation. J Heart Lung Transplant 2013;32:873–80.

  13. Alba AC, Rao V, Ivanov J, Ross HJ, Delgado DH. Usefulness of the INTERMACSscale to predict outcomes after mechanical assist device implantation. JHeart Lung Transplant 2009;28:827–33.

  14. Paniagua-Martin MJ, Marzoa-Rivas R, Campo-Perez R, et al. Usefulness of theINTERMACS Scale for predicting outcomes after urgent heart transplantation.Rev Esp Cardiol 2011;64:193–200.

  15. Guidelines from the Organ Procurement and Transplantation Network (OPTN),Organ Distribution: Allocation of Thoracic Organs. Department of Health and HumanServices, Health Resources and Services Administration, Healthcare SystemsBureau, Division of Transplantation. Available at: http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_9.pdf

  16. Frigerio M, Gronda EG,MangiavacchiM, Andreuzzi B, Colombo T, De Vita C, etal. Restrictive criteria for heart transplantation candidacy maximize survival ofpatients with advanced heart failure. J Heart Lung Transplant 1997;16:160–8.

  17. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. TheInternational Society of Heart and Lung Transplantation Guidelines for the care ofheart transplant recipients. J Heart Lung Transplant 2010;29:914–56.

  18. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Developmentand prospective validation of a clinical index to predict survival inambulatory patients referred for cardiac transplant evaluation. Circulation

  19. 1997;95:2660–7.19. Bjork JB, Anton KK et al: Defining Advance Heart Failure: A systematic reviewof criteria used in clinical trials. Journal of Cardiac Failure 2016; 22:569-77.

  20. Goda A, Williams P, Mancini D, Lund LH. Selecting patients for heart transplantation:comparison of the Heart Failure Survival Score (HFSS) and the Seattle heartfailure model (SHFM). J Heart Lung Transplant 2011;30:1236–43.

  21. Scrutinio D, Ammirati E, Guida P, Passantino A, Raimondo R, Guida V, et al. TheADHF/NT-proBNP risk score to predict 1-year mortality in hospitalized patientswith advanced decompensated heart failure. J Heart Lung Transplant 2013. http://dx.doi.org/10.1016/j.healun.2013.12.005 [Epub ahead of print].

  22. Senni M, Parrella P, De Maria R, Cottini C, Bohm M, Ponikowski P, et al. Predictingheart failure outcome from cardiac and comorbid conditions: the 3C-HF score.Int J Cardiol 2013;163:206–11.

  23. Gomez J. Paciente candidato a trasplante cardiaco. Revista Colombiana de Cardiologia.2016; 23(S1): 44-8.

  24. Lund L, Edwards L, Dipchand A, et al. The Registry of The International Societyof Heart and Lung Transplantation: Thirty-third Adult Hear Transplantation Report2016; Focus Theme: Primary Indications for transplant. The Journal of Heartand Lung Transplantation 2016;35.10:1158-69.

  25. Starling RC. Improved quantity and quality of life: A winning combination to treatadvanced heart failure. J Am Coll Cardiol 2010;55:1835-6.

  26. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2011 update: A report from the american heart association. Circulation2011;123:e18-e209

  27. Eckman PM. Immunosuppression in the sensitized heart transplant recipient. CurrOpin Organ Transplant 2010;15:650-6.

  28. Anand J,Mallidi HR. The State of the Art in Heart Transplantation. Semin ThoracicSurg 2013;25: 64-9.

  29. Schaffer JM, S ingh SK, Reitz BA, Oyer PE, Robbins RC, Mallidi HR.. Hearttransplant graft survivalis improved after a reduction in panel reactive antibodyactivity. J Thorac Cardiovasc Surg 2013;145:555–64.

  30. De Santo LS, Romano G, Maiello C, et al. Pulmonary artery hypertension inheart transplan trecipients:How much is too much? EurJ Cardiothorac Surg2012;42:864–9.

  31. Pons J, LeBlanc MH, Bernier M, et al. Effects of chronic sildenafil use on pulmonaryhemodynamics and clinical outcomes in heart transplantation. J Heart Lung-Transplant 2012;31:1281–7.

  32. Perez-Villa F, Farrero M, Cardona M, et al. Bosentan in heart transplantation candidateswith severe pulmonary hypertension: Efficacy, safety and outcome aftertransplantation. Clin Transplant 2013;27:25–31.

  33. Kettner J, Dorazilová S, Netuka I. Is severe pulmonary hypertension a contraindicationfor orthotopic heart transplantation? Not anymore. Physiol Res2011;60:769–75.

  34. Pauwaa S, Bhat G, Tatooles AJ, et al. How effective are continuous flow left ventricularassist devices in lowering high pulmonary artery pressures in heart transplantcandidates? Cardiol J 2012;19:153–8.

  35. Kutty RS, Parameshwar J, Lewis C, et al. Use of centrifugal left ventricular assistdevice as a bridge to candidacy in severe heart failure with secondary pulmonaryhypertension. Eur J Cardiothorac Surg 2013;43:1273-42.

  36. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction ofalloantibodies via proteosome inhibition in cardiac transplantation. J Heart LungTransplant 2011;30:1320-6.

  37. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenousimmunoglobulin G is effective in patients with elevated panel reactive antibodyprior to cardiac transplantation. J Heart Lung Transplant 1999;18:701-6.

  38. John R, Leitz K, Burke E, et al. Intravenous immunoglobulin reduces anti-HLAalloreactivity and shortens waiting time to cardiac transplantation in highly sensitizedleft ventricular assist device recipients. Circulation 1999; 100 (19 Suppl):II229-35.

  39. Kirklin JK, Naftel DC, Pagani FD, et al. Sixth intermacs annual report: A10,000-patient database. J Heart Lung Transplant 2014;33:555-64.

  40. Bunzel B, Laederach-Hofmann K, Wieselthaler G, Roethy W, Wolner E. Mechanicalcirculatory support as a bridge to heart transplantation: What remains?Long-term emotional sequelae in patients and spouses. J Heart Lung Transplant2007;26:384-9.

  41. Enciso JS. Evolving issues in heart failure management. Progress in CardiovascularDisease 2016;58:365-6.

  42. Kormos RL, Teuteberg JJ, Pagani FD, et al. Right ventricular failure in patientswith the HeartMate II continuous-flow left ventricular assist device: Incidence,risk factors, and effect on outcomes. J Thorac Cardiovasc Surg 2010;139:1316-24.

  43. Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failurerisk score a pre-operative tool for assessing the risk of right ventricular failurein left ventricular assist device candidates. J Am Coll Cardiol 2008;51:2163-72.

  44. Wever-Pinzon O, Drakos SG, Kfoury AG, et al. Morbidity and mortality in hearttransplant candidates supported with mechanical circulatory support: Is reappraisalof the current United network for organ sharing thoracic organ allocation policyjustified? Circulation 2013;127:452-62.

  45. Healy AH, Baird BC, Drakos SG, Stehlik J, Selzman CH. Impact of ventricularassist device complications on posttransplant survival: An analysis of the UnitedNetwork of Organ Sharing database. Ann Thorac Surg 2013;95:870-5.

  46. Cowger JA, Romano MA, Shah P, et al. Hemolysis: A harbinger of adverseoutcome after left ventricular assist device implant. J Heart Lung Transplant2014;33:35-43.

  47. Rose EA, Gelijns AC, Moskowitz AJ, et al; Randomized Evaluation of MechanicalAssistance for the Treatment of Congestive Heart Failure (REMATCH) StudyGroup. Long-term use of a left ventricular assist device for end-stage heart failure.N Engl J Med 2001;345:1435-43.

  48. Rogers JG, Aaronson KD, Boyle AJ, et al. HeartMate II Investigators. Continuousflow left ventricular assist device improves functional capacity and quality of lifeof advanced heart failure patients. J Am Coll Cardiol 2010;55:1826-34.

  49. Park SJ, Tector A, Piccioni W, et al. Left ventricular assist devices as destinationtherapy: a new look at survival. J Thorac Cardiovasc Surg 2005;129:9-17.

  50. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated withcontinuous-flow left ventricular assist device. N Engl J Med 2009;361:2241-51.

  51. Mancini D, Colombo P, et al. Left Ventricular Assist Device. A rapid evolvingalternative to trasplant. J Am Coll Cardiol 2015; 65: 2542-55.

  52. Wieselthaler GM, O’Driscoll G, Jansz P, Khaghani A, Strueber M; HVAD ClinicalInvestigators. Initial clinical experience with a novel left ventricular assist devicewith a magnetically levitated rotor in a multi-institutional trial. J Heart LungTransplant 2010;29:1218-25.

  53. Mussivand T, Hetzer R, Vitali E, et al. Clinical results with an ePTFE inflow conduitfor mechanical circulatory support. J Heart Lung Transplant 2004;23:1366-70.

  54. Sajgalik P, Grupper A, Edwards BS, et al. Current Status Left Ventricular AssistanceDevices. Mayo Clin Proc 2016; 91:927-40.

  55. Lund LH, Matthews J, Aaronson K. Patient selection for left ventricular assistdevices. Eur J Heart Fail 2010;12:434-43.

  56. Wilson SR, Mudge GH Jr, Stewart GC, Givertz MM. Evaluation for a ventricularassist device: selecting the appropriate candidate. Circulation 2009;119:2225-32.

  57. Oz MC, Rose EA, Slater J, Kuiper JJ, Catanese KA, Levin HR. Malignant ventriculararrhythmias are well tolerated in patients receiving long-term left ventricularassist devices. J Am Coll Cardiol 1994;24:1688-91.

  58. Peura JL, Colvin-Adams M, Francis GS, et al; American Heart Association HeartFailure and Transplantation Committee of the Council on Clinical Cardiology;Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation;Council on Cardiovascular Disease in the Young; Council on CardiovascularNursing; Council on Cardiovascular Radiology and Intervention; and Council onCardiovascular Surgery and Anesthesia. Recommendations for the use of mechanicalcirculatory support: device strategies and patient selection; a scientific statementfrom the American Heart Association. Circulation 2012;126:2648-67.

  59. Guerra F, Flori M, Bonelli P, Patani F, Capucci A. Electrical storm and heart failureworsening in implantable cardiac defibrillator patients. Europace. 2015;17:247-54.

  60. Kasirajan V, Tang DG, Katlaps GJ, Shah KB. The total artificial heart for biventricularheart failure and beyond. Curr Opin Cardiol 2012;27:301-7

  61. Shah SP, Mehra MR. Durable Left Ventricular Assist Device Therapy in AdvanceHeart Failure: Patient Selection and Clinical Outcomes. Indian Heart Journal2016; 68: s45-s51.

  62. Topilsky Y, Oh JK, Shah DK, et al. Echocardiographic predictors of adverse outcomesafter continuous left ventricular assist device implantation. J Am Coll CardiolImg 2011;4:211-22.

  63. Drakos SG, Janicki L, Horne BD, et al. Risk factors predictive of right ventricularfailure after left ventricular assist device implantation. Am J Cardiol2010;105:1030-5.

  64. Shah P, Mehta VM, Cowger JA, Aaronson KD, Pagani FD. Diagnosis of hemolysisand device thrombosis with lactate dehydrogenase during left ventricular assistdevice support. J Heart Lung Transplant 2014;33:102-4.

  65. Uriel N, Morrison KA, Garan AR, et al. Development of a novel echocardiographyramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. J Am CollCardiol 2012;60:1764-75.

  66. Starling RC, Moazami N, Silvestry SC, et al. Unexpected abrupt increase in leftventricular assist device thrombosis. N Engl J Med. 2014;370:33-40.




2020     |     www.medigraphic.com